Yu Hao

发布者:公共卫生学院发布时间:2022-10-25浏览次数:500

Professor of Biostatistics

Vicechair of Committee of Statistical Experts, Chinese Society of Clinical Oncology


haoyu@njmu.edu.cn

于浩,博士教授

Hao Yu, MD, PhD




Research Interest

Statistical methodology with applications in clinical trials and clinical epidemiology.



Education

Nanjing  Medical  University,  Preventive  Medicine , B.S. (1979.9-1984.7)

Nanjing  Medical University, Epidemiology  and  Biostatistics, M.S.(1993.9-1994.1)

Nanjing  University, Sociology, Ph.D. (2000.9-2003.12)


Honors and Awards:

2014  Teachers'  Scholarship  of  Nanjing  Medical  University


Research Projects

  • PI, Bayesian  statistical  methods of  phase II/III  seamless  design  in  clinical  trials. NSFC, 81273184

  • PI, On  the Statistical  Methods  of   Equivalence Test  for  Clinical  Trials  of  Generic Drugs. NSFC, 81773554


Selected Papers

  1. GengR, Song J, Zhong Z, Ni S, Liu W, He Z, Gan S, Huang Q, Yu H, Bai J, Liu J.Cross talk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma. Cancers(Basel). 2022,14(14):3383.

  2. NiS, Yu Q, Zhong Z, Yang M, Zhao Y, Wu J, Bai J, Yu H. Risk difference,relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpoint. J Biopharm Stat. 2022,1-16.

  3. NiS, Zhong Z, Wei J, Zhou J, Cai L, Yang M, Xun P, Zhao Y, Yu H, Bai J. Association between dietary in take of  polyunsaturated fatty acid and prevalence of hypertension in U.S. adults: A cross-sectional study using data from NHANES 2009-2016. Hypertens Res. 2022,45(3):516-526.

  4. Liu J, Wang Y, Yin J, Yang Y, Geng R, Zhong Z, Ni S, Liu W, Du M, Yu H, Bai J. Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy. J Oncol. 2022,2022:3477148.

  5. ZhouJ, Cai L, Ni S, Zhong Z, Yang M, Yu H, Zhao Y, Xun P, BaiJ. Associations of dietary PUFA with dyslipidaemia among the US adults: the findings from National Health and Nutrition Examination Survey (NHANES) 2009-2016. Br J Nutr. 2022,7: 1386-1394.

  6. QinF, Wu J, Chen F, Wei Y, Zhao Y, Jiang Z, Bai J, Yu H. Optimal, minimax and admissible two-stage design for phase II oncology clinicaltrials. BMC Med Res Methodol. 2020,20(1):126.

  7. HuangL, Wei Y, Shen S, Shi Q, Bai J, Li J, Qin S, Yu H, Chen F.The rapeutic effect of apatinib on overall survival is mediated byprolonged progression-free survival in advanced gastric cancer patients. Oncotarget. 2017,8(17):29346-29354.

  8. LiZ, Xin J, Chen W, Liu J, Zhu M, Zhao C, Yuan J, Jin G, Ma H, Du J,Hu Z, WuT, Shen H, Dai J, Yu H. Genetic variantsin autophagy associated genes are associated with DNA damage levels in Chinese population. Gene. 2017,626:414-419.

  9. TianT, Xiao L, Du J, Zhu X, Gu Y, Qin N, Yan C, Liu L, Ma H, Jiang Y,Chen J, Yu H,Dai J. Polymorphisms in CARS are associated with gastric cancer risk: at wo-stage case-control study in the Chinese population.Gastric Cancer.2017,20(6):940-947.

  10. JiangY, Du F, Chen F, Qin N, Jiang Z, Zhou J, Jiang T, Pu Z, Cheng Y,Chen J, Dai J, Ma H, Jin G, Hu Z, Yu H, Shen H.Potentially functional variants in lncRNAs are associated with breast cancer risk in a Chinese population. Mol Carcinog.2017,56(9):2048-2057.